{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:13Z","timestamp":1789610893253,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There is no known biomarker that predicts the response to immune therapy in autoimmune synaptic encephalitis. Thus, we investigated serum albumin as a prognostic biomarker of early immune therapies in patients with autoimmune encephalitis. We enrolled patients who were diagnosed with definite autoimmune encephalitis and underwent IVIg treatment at Seoul National University Hospital from 2012 to 2017. Patients were dichotomized according to serum albumin prior to IVIg administration with a cut-off level of 4.0\u2009g\/dL, which was the median value of 50% of patients. Seventeen (53.1%) of the 32 patients with definite autoimmune encephalitis who received IVIg treatment in our hospital had low serum albumin (&lt;4.0\u2009g\/dL). The initial disease severity (mRS\u2009\u2265\u20094) was the sole factor that predicted low albumin in autoimmune encephalitis patients using multivariate analysis (P\u2009=\u20090.013). The low albumin group exhibited a worse response to immune therapy at the third and fourth weeks from IVIg administration (P\u2009&lt;\u20090.01 and P\u2009=\u20090.012, respectively), and recovery to activities of daily life without assistance was faster in the high albumin group (log-rank test for trend, P\u2009&lt;\u20090.01). Our study found that pretreatment low serum albumin was a significant indicator of autoimmune encephalitis prognosis in the short-term and long-term.<\/jats:p>","DOI":"10.1038\/s41598-018-19490-z","type":"journal-article","created":{"date-parts":[[2018,1,11]],"date-time":"2018-01-11T11:36:00Z","timestamp":1515670560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis"],"prefix":"10.1038","volume":"8","author":[{"given":"Yoonhyuk","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sun","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsup","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Il","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"19490_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 15, 391\u2013404, https:\/\/doi.org\/10.1016\/s1474-4422(15)00401-9 (2016).","journal-title":"The Lancet Neurology"},{"key":"19490_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3988\/jcn.2014.10.2.157","volume":"10","author":"J-A Lim","year":"2014","unstructured":"Lim, J.-A. et al. Anti-N-Methyl-D-Aspartate Receptor Encephalitis in Korea: Clinical Features, Treatment, and Outcome. Journal of Clinical Neurology (Seoul, Korea) 10, 157\u2013161, https:\/\/doi.org\/10.3988\/jcn.2014.10.2.157 (2014).","journal-title":"Journal of Clinical Neurology (Seoul, Korea)"},{"key":"19490_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jneuroim.2016.02.002","volume":"293","author":"J-I Byun","year":"2016","unstructured":"Byun, J.-I. et al. Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. Journal of Neuroimmunology 293, 34\u201338, https:\/\/doi.org\/10.1016\/j.jneuroim.2016.02.002 (2016).","journal-title":"Journal of Neuroimmunology"},{"key":"19490_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology 12, 157\u2013165, https:\/\/doi.org\/10.1016\/S1474-4422(12)70310-1 (2013).","journal-title":"The Lancet Neurology"},{"key":"19490_CR5","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","volume":"86","author":"W-J Lee","year":"2016","unstructured":"Lee, W.-J. et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 86, 1683\u20131691, https:\/\/doi.org\/10.1212\/WNL.0000000000002635 (2016).","journal-title":"Neurology"},{"key":"19490_CR6","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","volume":"13","author":"W-J Lee","year":"2016","unstructured":"Lee, W.-J. et al. Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics 13, 824\u2013832, https:\/\/doi.org\/10.1007\/s13311-016-0442-6 (2016).","journal-title":"Neurotherapeutics"},{"key":"19490_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","volume":"74","author":"C Finke","year":"2017","unstructured":"Finke, C. et al. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA neurology 74, 50\u201359, https:\/\/doi.org\/10.1001\/jamaneurol.2016.4226 (2017).","journal-title":"JAMA neurology"},{"key":"19490_CR8","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","volume":"15","author":"T Kelesidis","year":"2011","unstructured":"Kelesidis, T., Daikos, G., Boumpas, D. & Tsiodras, S. Does rituximab increase the incidence of infectious complications? A narrative review. International Journal of Infectious Diseases 15, e2\u2013e16, https:\/\/doi.org\/10.1016\/j.ijid.2010.03.025 (2011).","journal-title":"International Journal of Infectious Diseases"},{"key":"19490_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","volume":"51","author":"VR Lang","year":"2012","unstructured":"Lang, V. R. et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology 51, 852\u2013857, https:\/\/doi.org\/10.1093\/rheumatology\/ker223 (2012).","journal-title":"Rheumatology"},{"key":"19490_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/bja\/85.4.599","volume":"85","author":"JP Nicholson","year":"2000","unstructured":"Nicholson, J. P., Wolmarans, M. R. & Park, G. R. The role of albumin in critical illness. BJA: British Journal of Anaesthesia 85, 599\u2013610, https:\/\/doi.org\/10.1093\/bja\/85.4.599 (2000).","journal-title":"BJA: British Journal of Anaesthesia"},{"key":"19490_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2891-9-69","volume":"9","author":"D Gupta","year":"2010","unstructured":"Gupta, D. & Lis, C. G. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutrition Journal 9, 1\u201316, https:\/\/doi.org\/10.1186\/1475-2891-9-69 (2010).","journal-title":"Nutrition Journal"},{"key":"19490_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ahj.2007.11.043","volume":"155","author":"TB Horwich","year":"2008","unstructured":"Horwich, T. B., Kalantar-Zadeh, K., MacLellan, R. W. & Fonarow, G. C. Albumin levels predict survival in patients with systolic heart failure. American Heart Journal 155, 883\u2013889, https:\/\/doi.org\/10.1016\/j.ahj.2007.11.043 (2008).","journal-title":"American Heart Journal"},{"key":"19490_CR13","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.ahj.2010.09.004","volume":"160","author":"S Uthamalingam","year":"2010","unstructured":"Uthamalingam, S. et al. Serum albumin and mortality in acutely decompensated heart failure. American Heart Journal 160, 1149\u20131155, https:\/\/doi.org\/10.1016\/j.ahj.2010.09.004 (2010).","journal-title":"American Heart Journal"},{"key":"19490_CR14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1651-2227.2010.01875.x","volume":"99","author":"HC Kuo","year":"2010","unstructured":"Kuo, H. C. et al. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatrica 99, 1578\u20131583, https:\/\/doi.org\/10.1111\/j.1651-2227.2010.01875.x (2010).","journal-title":"Acta Paediatrica"},{"key":"19490_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","volume":"74","author":"W-JR Fokkink","year":"2016","unstructured":"Fokkink, W.-J. R. et al. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin\u2013Treated Guillain-Barr\u00e9 Syndrome. JAMA Neurology 74, 189\u2013196, https:\/\/doi.org\/10.1001\/jamaneurol.2016.4480 (2016).","journal-title":"JAMA Neurology"},{"key":"19490_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nature Reviews Immunology 13, 176\u2013189, https:\/\/doi.org\/10.1038\/nri3401 (2013).","journal-title":"Nature Reviews Immunology"},{"key":"19490_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(09)70324-2","volume":"9","author":"E Lancaster","year":"2010","unstructured":"Lancaster, E. et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet Neurology 9, 67\u201376, https:\/\/doi.org\/10.1016\/S1474-4422(09)70324-2 (2010).","journal-title":"The Lancet Neurology"},{"key":"19490_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14581\/jer.16010","volume":"6","author":"S Lee","year":"2016","unstructured":"Lee, S. & Lee, S.-T. The Laboratory Diagnosis of Autoimmune Encephalitis. Journal of Epilepsy Research 6, 45\u201350, https:\/\/doi.org\/10.14581\/jer.16010 (2016).","journal-title":"Journal of Epilepsy Research"},{"key":"19490_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine 130, 461\u2013470 (1999).","journal-title":"Annals of internal medicine"},{"key":"19490_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J. & van Gijn, J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19, 604\u2013607 (1988).","journal-title":"Stroke"},{"key":"19490_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.mam.2011.12.002","volume":"33","author":"G Fanali","year":"2012","unstructured":"Fanali, G. et al. Human serum albumin: from bench to bedside. Molecular aspects of medicine 33, 209\u2013290, https:\/\/doi.org\/10.1016\/j.mam.2011.12.002 (2012).","journal-title":"Molecular aspects of medicine"},{"key":"19490_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1161\/01.RES.32.5.643","volume":"32","author":"HP Parving","year":"1973","unstructured":"Parving, H. P. & Gyntelberg, F. Transcapillary escape rate of albumin and plasma volume in essential hypertension. Circulation research 32, 643\u2013651 (1973).","journal-title":"Circulation research"},{"key":"19490_CR23","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/sj.mn.7800211","volume":"10","author":"A Houben","year":"2003","unstructured":"Houben, A., Beljaars, J. H., Hofstra, L. E. O., Kroon, A. A. & Leeuw, P. W. Microvascular Abnormalities in Chronic Heart Failure: A Cross\u2010Sectional Analysis. Microcirculation 10, 471\u2013478, https:\/\/doi.org\/10.1038\/sj.mn.7800211 (2003).","journal-title":"Microcirculation"},{"key":"19490_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome. Annals of neurology 66, 597\u2013603, https:\/\/doi.org\/10.1002\/ana.21737 (2009).","journal-title":"Annals of neurology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19490-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T20:10:47Z","timestamp":1671567047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19490"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19490-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1012"}}